Merck EVP, general counsel Jennifer Zachary sells $10.7m in stock

Executive Vice President and General Counsel Jennifer Zachary of Merck & Co., Inc., sold a substantial amount of the company's shares, approximately $10.7 million, on August 12, 2026. This sale was the result of both exercising stock options and selling her shares directly. During the day of transactions, Zachary disposed of 80,315 shares, trading at prices between $133.0300 and $133.5000, with a weighted average price of $133.4557 per share.

Earlier on the same day, she acquired 54,927 shares via stock options, including 41,494 shares at $117.89 each and 13,433 shares at $84.71 each, leading to a total acquisition value of $6,029,637. As a result of these transactions, Zachary now owns 45,509.254 shares of Merck & Co., Inc. She reported these transactions to the Securities and Exchange Commission on August 13, 2026.

Meanwhile, Merck reported its Q2 2026 financials, surpassing expectations with a $0.13 loss per share and $16.6 billion in revenue. This success was attributed to strong sales in oncology, vaccines, and newer products. In response, Merck raised its full-year outlook and appointed Bart Gourley as Chief AI Officer, adding to the company's innovative capacity.

Argus Research raised its price target for Merck stock to $145, citing the company's portfolio strength and maintaining a Buy rating. Despite a $5.7 billion charge from the Terns Pharmaceuticals acquisition, Merck's diverse portfolio and products like KEYTRUDA enabled the company to maintain robust quarterly results.